Cognition Therapeutics Sees 86% Neuropsychiatric Decline Slowed in DLB Phase 2 Trial
Cognition Therapeutics’ Phase 2 COG1201 SHIMMER trial in mild-to-moderate dementia with Lewy bodies showed zervimesine treatment slowed neuropsychiatric decline by 86% on the NPI-12 versus placebo. The company plans a late-stage DLB psychosis trial following FDA Type C feedback on these robust findings.
1. Phase 2 SHIMMER Analysis
In the Phase 2 COG1201 SHIMMER study in mild-to-moderate DLB patients, zervimesine treatment reduced neuropsychiatric decline by 86% on the NPI-12 versus placebo. Treatment benefits extended across behavioral, cognitive, motor and global function domains, highlighting robust responses in agitation, hallucinations and anxiety components of the neuropsychiatric index.
2. Zervimesine’s Mechanism and Tolerability
Zervimesine’s unique disease-modifying mechanism targets toxic oligomer pathways to slow disease progression, unlike acute antipsychotics that treat individual symptoms. The therapy demonstrated directionally favorable impacts on cognitive fluctuations, memory, movement symptoms and daily living activities, and is well tolerated in DLB patients unable to use traditional antipsychotics.
3. Development Plans
Based on these strong Phase 2 results and a recent FDA Type C meeting, the company plans to launch a late-stage clinical trial for DLB psychosis. This program aims to address hallucinations, delusions, agitation and anxiety in DLB patients with a therapy that may be safer than current antipsychotic options.